Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 4741
Special Issue Editors
Interests: connexin; immune response; tumor cells; cancer therapy; biomarkers; antitumor immunotherapies
2. Millennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile
3. Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden
Interests: tumor immunology; cancer immunotherapy; dendritic cells
Special Issue Information
Dear Colleagues,
The landscape of cancer treatment has undergone a remarkable transformation with the advent of immune checkpoint inhibitors (ICIs). These groundbreaking therapies have ushered in a new era in the fight against cancer by unleashing the power of the immune system to target and destroy malignant cells. Concurrently, cellular immunotherapies have emerged as a promising treatment frontier, offering personalized and precise approaches to combat this complex disease. Cell-mediated immunity can eliminate cancer cells and provide durable remissions. This Special Issue, entitled "Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment," aims to provide a comprehensive overview of the latest developments in this dynamic field, including dendritic cell-based vaccines, whole-tumor-cell vaccines, and adoptive cell (T-cell, NK cell, or CAR-T cell) transfer.
Dr. Andrés Tittarelli
Dr. Flavio Salazar-Onfray
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR-T cells
- NK-cell immunotherapy
- adoptive T-cell transfer
- dendritic cell cancer vaccines
- whole-tumor-cell vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
